Study to Investigate CSL112 in Subjects With Acute | Clinical Research Studies Listing

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Recruiting

18 years - 99 years

All

Phase 3

1000 participants needed

1 Location

Brief description of study

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Acute Coronary Syndrome
Age: 18 years - 99 years
Gender: All

Male or Female, Age 18 or older, Evidence of myocardial necrosis, consistent with type I (spontaneous) MI

Updated on 04 Aug 2024. Study ID: 829891

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Brief description of study

Eligibility of study

Find a site

Interested in the study